LAMEA IVD Market by Product Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Blood Testing, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Other Indications), and by End Users (Standalone Laboratory, Hospitals, Academic and Medical Schools, Point of Care Testing, and Others) - Opportunity Analysis and Industry Forecast, 2017-2023
IVD are the medical diagnostic devices comprised of any reagent, calibrator, control material, kit, specimen receptacle, software, instrument, apparatus, equipment, or system used alone or in combination with other diagnostic devices, specifically designed for in vitro examination of specimens of human body.
Increase in incidences of chronic and infectious diseases such as tuberculosis, cancer, HIV and others drive the market. Furthermore, rapid expansion of government healthcare expenditure is anticipated to increase the demand of diagnosis, thereby fueling the market growth. In addition, rise in awareness of personalized medicine and increase in awareness of preventive healthcare measures boost the market share. However, stringent government regulations associated with the safety and efficacy of IVD products is expected to hinder the growth of the market during the forecast period. The emerging economies of the LAMEA regions offer lucrative growth opportunities to IVD during the forecast period. The LAMEA IVD market accounted for $7,413 million in 2016, and is estimated to reach at $10,316 million by 2023, growing at a CAGR of 4.7% from 2017 to 2023.
The market is segmented on the basis of product type, techniques, application, end user, and country. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of techniques, it is divided into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study includes infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end user, it is classified into hospitals, academic and medical schools, point of care testing, and others. By geography, it is analyzed across Latin America, Middle East, and Africa.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the LAMEA IVD market, with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report provides a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand various products of the market.
Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product Type
Reagents
Instruments
Software and Services
By Techniques
Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassays (CLIAS)
Fluorescence Immunoassays (FIAS)
Colorimetric Immunoassays (CIS)
Rapid Tests
Enzyme-Linked Immunospot Assays (ELISPOT)
Radioimmunoassay
Western Blot
Blood Testing
Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Hybridization
DNA Diagnostics
Microarrays
Others
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Lipid Profile
Thyroid Function Panel
Renal Profile
Electrolyte Panel
Specialty Chemicals
Other IVD Techniques
By Application
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Other Indications
By End Users
Standalone Laboratory
Hospitals
Academic and Medical Schools
Point of Care Testing
Others
By Country
Latin America
Middle East
Africa
List of players profiled in the report
Thermo Fisher Scientific Inc.
Alere Inc.
Biomerieux
Danaher Corporation
F. Hoffmann-La Roche AG
Becton Dickinson and Company
Bio-Rad Laboratories
Bayer AG
Sysmex Corporation
Johnson & Johnson
Increase in incidences of chronic and infectious diseases such as tuberculosis, cancer, HIV and others drive the market. Furthermore, rapid expansion of government healthcare expenditure is anticipated to increase the demand of diagnosis, thereby fueling the market growth. In addition, rise in awareness of personalized medicine and increase in awareness of preventive healthcare measures boost the market share. However, stringent government regulations associated with the safety and efficacy of IVD products is expected to hinder the growth of the market during the forecast period. The emerging economies of the LAMEA regions offer lucrative growth opportunities to IVD during the forecast period. The LAMEA IVD market accounted for $7,413 million in 2016, and is estimated to reach at $10,316 million by 2023, growing at a CAGR of 4.7% from 2017 to 2023.
The market is segmented on the basis of product type, techniques, application, end user, and country. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of techniques, it is divided into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study includes infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end user, it is classified into hospitals, academic and medical schools, point of care testing, and others. By geography, it is analyzed across Latin America, Middle East, and Africa.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the LAMEA IVD market, with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report provides a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand various products of the market.
Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product Type
Reagents
Instruments
Software and Services
By Techniques
Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassays (CLIAS)
Fluorescence Immunoassays (FIAS)
Colorimetric Immunoassays (CIS)
Rapid Tests
Enzyme-Linked Immunospot Assays (ELISPOT)
Radioimmunoassay
Western Blot
Blood Testing
Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Hybridization
DNA Diagnostics
Microarrays
Others
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Lipid Profile
Thyroid Function Panel
Renal Profile
Electrolyte Panel
Specialty Chemicals
Other IVD Techniques
By Application
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Other Indications
By End Users
Standalone Laboratory
Hospitals
Academic and Medical Schools
Point of Care Testing
Others
By Country
Latin America
Middle East
Africa
List of players profiled in the report
Thermo Fisher Scientific Inc.
Alere Inc.
Biomerieux
Danaher Corporation
F. Hoffmann-La Roche AG
Becton Dickinson and Company
Bio-Rad Laboratories
Bayer AG
Sysmex Corporation
Johnson & Johnson
CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 KEY BENEFITS
1.3 KEY MARKET SEGMENTS
1.4 RESEARCH METHODOLOGY
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 PORTERS FIVE FORCES ANALYSIS
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry
3.4 MARKET SHARE ANALYSIS, 2016
3.5 MARKET DYNAMICS
3.5.1 Drivers
3.5.1.1 Increasing incidence of chronic and infectious diseases
3.5.1.2 Technological advancements in IVD
3.5.1.3 Emergence of minimal invasive technologies
3.5.1.4 Increasing government expenditures on healthcare
3.5.1.5 Increase in popularity of personalized medicine approach
3.5.2 Restraint
3.5.2.1 Unclear reimbursement policies
3.5.2.2 Stringent regulatory policies
3.5.3 Opportunity
3.5.3.1 Potential opportunities for outsourcing
3.5.3.2 Convergence of new technologies
CHAPTER 4 IVD MARKET, BY PRODUCT TYPE
4.1 OVERVIEW
4.1.1 Market size and forecast
4.2 REAGENTS
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 INSTRUMENTS
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 SOFTWARE AND SERVICES
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
CHAPTER 5 IVD MARKET, BY TECHNIQUE
5.1 OVERVIEW
5.1.1 Market size and forecast
5.2 IMMUNODIAGNOSTICS
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 Enzyme-linked immunosorbent assay (ELISA)
5.2.4.1 Market size and forecast
5.2.4.2 Chemiluminescence immunoassay (CLIA)
5.2.4.2.1 Market size and forecast
5.2.4.3 Fluorescence immunoassay (FIA)
5.2.4.3.1 Market size and forecast
5.2.4.4 Colorimetric immunoassay (CI)
5.2.4.4.1 Market size and forecast
5.2.5 Rapid tests
5.2.5.1 Market size and forecast
5.2.6 Enzyme-linked immunospot (ELISPOT)
5.2.6.1 Market size and forecast
5.2.7 Radioimmunoassay (RIA)
5.2.7.1 Market size and forecast
5.2.8 Western blot
5.2.8.1 Market size and forecast
5.3 BLOOD TESTING
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.4 MOLECULAR DIAGNOSTICS
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 Polymerize chain reaction (PCR)
5.4.4.1 Market size and forecast
5.4.5 Isothermal nucleic acid technology (INAAT)
5.4.5.1 Market size and forecast
5.4.6 Hybridization
5.4.6.1 Market size and forecast
5.4.7 DNA diagnostics
5.4.7.1 Market size and forecast
5.4.8 Microarray
5.4.8.1 Market size and forecast
5.4.9 Others
5.4.9.1 Market size and forecast
5.5 TISSUE DIAGNOSTICS
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.6 CLINICAL CHEMISTRY
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.6.4 Basic metabolic panel
5.6.4.1 Market size and forecast
5.6.5 Liver panel
5.6.5.1 Market size and forecast
5.6.6 Renal profile
5.6.6.1 Market size and forecast
5.6.7 Lipid profile
5.6.7.1 Market size and forecast
5.6.8 Thyroid function panel
5.6.8.1 Market size and forecast
5.6.9 Electrolyte panel
5.6.9.1 Market size and forecast
5.6.10 Speciality chemicals
5.6.10.1 Market size and forecast
5.7 OTHER IVD TECHNIQUES
5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast
CHAPTER 6 IVD MARKET, BY APPLICATION
6.1 INFECTIOUS DISEASES
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.2 CANCER
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.3 CARDIAC DISEASES
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.4 IMMUNE SYSTEM DISORDERS
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.5 NEPHROLOGICAL DISEASES
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.6 GASTROINTESTINAL DISEASES
6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast
6.7 OTHERS INDICATIONS
6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast
CHAPTER 7 IVD MARKET BY END USERS
7.1 STANDALONE LABORATORIES
7.1.1 Market size and forecast
7.2 HOSPITALS
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 ACADEMIC AND MEDICAL SCHOOLS
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 POINT OF CARE TESTING
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.5 OTHERS END-USER
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
CHAPTER 8 LAMEA IVD MARKET
8.1 Key market trends
8.2 Key growth factors and opportunities
8.3 Market size and forecast
8.4 Latin America
8.4.1 Market size and forecast
8.5 Middle East
8.5.1 Market size and forecast
8.6 Africa
8.4.6.1 Market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 THERMO FISHER SCIENTIFIC INC.
9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and development
9.2 ALERE INC.
9.2.1 Company overview
9.2.2 Business performance
9.2.3 Key strategies and developments
9.3 BIOMERIEUX
9.3.1 Company overview
9.3.2 Business performance
9.3.3 Key strategies and developments
9.4 DANAHER CORPORATION
9.4.1 Company overview
9.4.2 Business performance
9.4.3 Key strategies and development
9.5 F. HOFFMANN-LA ROCHE AG
9.5.1 Company overview
9.5.2 Business performance
9.5.3 Key strategies and developments
9.6 BECTON DICKINSON AND COMPANY
9.6.1 Company overview
9.6.2 Business performance
9.6.3 Key strategies and development
9.7 BIO-RAD LABORATORIES
9.7.1 Company overview
9.7.2 Business performance
9.7.3 Key strategies and developments
9.8 BAYER AG
9.8.1 Company overview
9.8.2 Business performance
9.8.3 Key strategies and development
9.9 SYSMEX CORPORATION
9.9.1 Company overview
9.9.2 Business performance
9.9.3 Key strategies and developments
9.10 JOHNSON & JOHNSON
9.10.1 Company overview
9.10.2 Business performance
9.10.3 Key strategies and development
1.1 REPORT DESCRIPTION
1.2 KEY BENEFITS
1.3 KEY MARKET SEGMENTS
1.4 RESEARCH METHODOLOGY
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 PORTERS FIVE FORCES ANALYSIS
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry
3.4 MARKET SHARE ANALYSIS, 2016
3.5 MARKET DYNAMICS
3.5.1 Drivers
3.5.1.1 Increasing incidence of chronic and infectious diseases
3.5.1.2 Technological advancements in IVD
3.5.1.3 Emergence of minimal invasive technologies
3.5.1.4 Increasing government expenditures on healthcare
3.5.1.5 Increase in popularity of personalized medicine approach
3.5.2 Restraint
3.5.2.1 Unclear reimbursement policies
3.5.2.2 Stringent regulatory policies
3.5.3 Opportunity
3.5.3.1 Potential opportunities for outsourcing
3.5.3.2 Convergence of new technologies
CHAPTER 4 IVD MARKET, BY PRODUCT TYPE
4.1 OVERVIEW
4.1.1 Market size and forecast
4.2 REAGENTS
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 INSTRUMENTS
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 SOFTWARE AND SERVICES
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
CHAPTER 5 IVD MARKET, BY TECHNIQUE
5.1 OVERVIEW
5.1.1 Market size and forecast
5.2 IMMUNODIAGNOSTICS
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 Enzyme-linked immunosorbent assay (ELISA)
5.2.4.1 Market size and forecast
5.2.4.2 Chemiluminescence immunoassay (CLIA)
5.2.4.2.1 Market size and forecast
5.2.4.3 Fluorescence immunoassay (FIA)
5.2.4.3.1 Market size and forecast
5.2.4.4 Colorimetric immunoassay (CI)
5.2.4.4.1 Market size and forecast
5.2.5 Rapid tests
5.2.5.1 Market size and forecast
5.2.6 Enzyme-linked immunospot (ELISPOT)
5.2.6.1 Market size and forecast
5.2.7 Radioimmunoassay (RIA)
5.2.7.1 Market size and forecast
5.2.8 Western blot
5.2.8.1 Market size and forecast
5.3 BLOOD TESTING
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.4 MOLECULAR DIAGNOSTICS
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 Polymerize chain reaction (PCR)
5.4.4.1 Market size and forecast
5.4.5 Isothermal nucleic acid technology (INAAT)
5.4.5.1 Market size and forecast
5.4.6 Hybridization
5.4.6.1 Market size and forecast
5.4.7 DNA diagnostics
5.4.7.1 Market size and forecast
5.4.8 Microarray
5.4.8.1 Market size and forecast
5.4.9 Others
5.4.9.1 Market size and forecast
5.5 TISSUE DIAGNOSTICS
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.6 CLINICAL CHEMISTRY
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.6.4 Basic metabolic panel
5.6.4.1 Market size and forecast
5.6.5 Liver panel
5.6.5.1 Market size and forecast
5.6.6 Renal profile
5.6.6.1 Market size and forecast
5.6.7 Lipid profile
5.6.7.1 Market size and forecast
5.6.8 Thyroid function panel
5.6.8.1 Market size and forecast
5.6.9 Electrolyte panel
5.6.9.1 Market size and forecast
5.6.10 Speciality chemicals
5.6.10.1 Market size and forecast
5.7 OTHER IVD TECHNIQUES
5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast
CHAPTER 6 IVD MARKET, BY APPLICATION
6.1 INFECTIOUS DISEASES
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.2 CANCER
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.3 CARDIAC DISEASES
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.4 IMMUNE SYSTEM DISORDERS
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.5 NEPHROLOGICAL DISEASES
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.6 GASTROINTESTINAL DISEASES
6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast
6.7 OTHERS INDICATIONS
6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast
CHAPTER 7 IVD MARKET BY END USERS
7.1 STANDALONE LABORATORIES
7.1.1 Market size and forecast
7.2 HOSPITALS
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 ACADEMIC AND MEDICAL SCHOOLS
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 POINT OF CARE TESTING
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.5 OTHERS END-USER
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
CHAPTER 8 LAMEA IVD MARKET
8.1 Key market trends
8.2 Key growth factors and opportunities
8.3 Market size and forecast
8.4 Latin America
8.4.1 Market size and forecast
8.5 Middle East
8.5.1 Market size and forecast
8.6 Africa
8.4.6.1 Market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 THERMO FISHER SCIENTIFIC INC.
9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and development
9.2 ALERE INC.
9.2.1 Company overview
9.2.2 Business performance
9.2.3 Key strategies and developments
9.3 BIOMERIEUX
9.3.1 Company overview
9.3.2 Business performance
9.3.3 Key strategies and developments
9.4 DANAHER CORPORATION
9.4.1 Company overview
9.4.2 Business performance
9.4.3 Key strategies and development
9.5 F. HOFFMANN-LA ROCHE AG
9.5.1 Company overview
9.5.2 Business performance
9.5.3 Key strategies and developments
9.6 BECTON DICKINSON AND COMPANY
9.6.1 Company overview
9.6.2 Business performance
9.6.3 Key strategies and development
9.7 BIO-RAD LABORATORIES
9.7.1 Company overview
9.7.2 Business performance
9.7.3 Key strategies and developments
9.8 BAYER AG
9.8.1 Company overview
9.8.2 Business performance
9.8.3 Key strategies and development
9.9 SYSMEX CORPORATION
9.9.1 Company overview
9.9.2 Business performance
9.9.3 Key strategies and developments
9.10 JOHNSON & JOHNSON
9.10.1 Company overview
9.10.2 Business performance
9.10.3 Key strategies and development
LIST OF TABLES
TABLE 1 INCIDENCE OF DISEASES
TABLE 2 LAMEA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 3 LAMEA IVD REAGENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 4 LAMEA IVD INSTRUMENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 5 LAMEA IVD SOFTWARE & SERVICES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 6 LAMEA IVD MARKET BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 7 LAMEA IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY TYPES, 2016-2023 ($MILLION)
TABLE 8 LAMEA IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY COUNTRY,2016-2023 ($MILLION)
TABLE 9 LAMEA IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET FOR ELISA, BY TYPES, 2016-2023 ($MILLION)
TABLE 10 LAMEA IVD BLOOD TESTING TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11 LAMEA IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 12 LAMEA IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 13 LAMEA IVD TISSUE DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 14 LAMEA IVD CLINICAL CHEMISTRY TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 15 LAMEA OTHER IVD TECHNIQUES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 16 LAMEA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17 LAMEA IVD INFECTIOUS DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18 LAMEA IVD CANCER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19 LAMEA IVD CARDIAC DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20 LAMEA IVD IMMUNE SYSTEM DISORDER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 21 LAMEA IVD NEPHROLOGICAL DISEASES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 22 LAMEA IVD GASTROINTESTINAL DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23 LAMEA IVD OTHER INDICATION MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24 LAMEA IVD MARKET, BY END USER, 2016-2023, ($MILLION)
TABLE 25 LAMEA IVD STANDALONE LABORATORIES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 26 LAMEA IVD HOSPITALS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27 LAMEA IVD ACADEMIC AND MEDICAL SCHOOLS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 28 LAMEA IVD POINT OF CARE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29 LAMEA IVD OTHER END-USER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 30 LAMEA IVD MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31 LAMEA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 32 LAMEA IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 33 LAMEA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34 LAMEA IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 35 LATIN AMERICA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 36 LATIN AMERICA IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 37 LATIN AMERICA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38 LATIN AMERICA IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 39 MIDDLE EAST IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 40 MIDDLE EAST IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 41 MIDDLE EAST IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 42 MIDDLE EAST IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 43 AFRICA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 44 AFRICA IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 45 AFRICA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46 AFRICA IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 47 THERMO FISHER SCIENTIFIC INC. COMPANY SNAPSHOT
TABLE 48 ALERE INC. COMPANY SNAPSHOT
TABLE 49 BIOMERIEUX COMPANY SNAPSHOT
TABLE 50 DANAHER CORPORATION COMPANY SNAPSHOT
TABLE 51 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 52 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 53 BIO-RAD LABORATORIES, INC. COMAPNY SNAPSHOT
TABLE 54 BAYER AG COMPANY SNAPSHOT
TABLE 55 SYSMEX CORPORATION COMPANY SNAPSHOT
TABLE 56 JOHNSON & JOHNSON PVT LTD. COMPANY SNAPSHOT
TABLE 1 INCIDENCE OF DISEASES
TABLE 2 LAMEA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 3 LAMEA IVD REAGENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 4 LAMEA IVD INSTRUMENTS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 5 LAMEA IVD SOFTWARE & SERVICES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 6 LAMEA IVD MARKET BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 7 LAMEA IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY TYPES, 2016-2023 ($MILLION)
TABLE 8 LAMEA IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY COUNTRY,2016-2023 ($MILLION)
TABLE 9 LAMEA IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET FOR ELISA, BY TYPES, 2016-2023 ($MILLION)
TABLE 10 LAMEA IVD BLOOD TESTING TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11 LAMEA IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 12 LAMEA IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 13 LAMEA IVD TISSUE DIAGNOSTICS TECHNIQUE MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 14 LAMEA IVD CLINICAL CHEMISTRY TECHNIQUE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 15 LAMEA OTHER IVD TECHNIQUES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 16 LAMEA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17 LAMEA IVD INFECTIOUS DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18 LAMEA IVD CANCER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19 LAMEA IVD CARDIAC DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20 LAMEA IVD IMMUNE SYSTEM DISORDER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 21 LAMEA IVD NEPHROLOGICAL DISEASES MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 22 LAMEA IVD GASTROINTESTINAL DISEASES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 23 LAMEA IVD OTHER INDICATION MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24 LAMEA IVD MARKET, BY END USER, 2016-2023, ($MILLION)
TABLE 25 LAMEA IVD STANDALONE LABORATORIES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 26 LAMEA IVD HOSPITALS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27 LAMEA IVD ACADEMIC AND MEDICAL SCHOOLS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 28 LAMEA IVD POINT OF CARE MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29 LAMEA IVD OTHER END-USER MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 30 LAMEA IVD MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31 LAMEA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 32 LAMEA IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 33 LAMEA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34 LAMEA IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 35 LATIN AMERICA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 36 LATIN AMERICA IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 37 LATIN AMERICA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38 LATIN AMERICA IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 39 MIDDLE EAST IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 40 MIDDLE EAST IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 41 MIDDLE EAST IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 42 MIDDLE EAST IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 43 AFRICA IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 44 AFRICA IVD MARKET, BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 45 AFRICA IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46 AFRICA IVD MARKET, BY END-USER, 2016-2023 ($MILLION)
TABLE 47 THERMO FISHER SCIENTIFIC INC. COMPANY SNAPSHOT
TABLE 48 ALERE INC. COMPANY SNAPSHOT
TABLE 49 BIOMERIEUX COMPANY SNAPSHOT
TABLE 50 DANAHER CORPORATION COMPANY SNAPSHOT
TABLE 51 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 52 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 53 BIO-RAD LABORATORIES, INC. COMAPNY SNAPSHOT
TABLE 54 BAYER AG COMPANY SNAPSHOT
TABLE 55 SYSMEX CORPORATION COMPANY SNAPSHOT
TABLE 56 JOHNSON & JOHNSON PVT LTD. COMPANY SNAPSHOT
LIST OF FIGURES
FIGURE 1 MARKET SEGMENTATION
FIGURE 2 TOP INVESTMENT POCKETS
FIGURE 3 TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4 TOP WINNING STRATEGIES: NATURE AND TYPE, 2014-2016
FIGURE 5 PORTERS FIVE FORCES ANALYSIS
FIGURE 6 MARKET SHARE ANALYSIS: IVD MARKET, 2016
FIGURE 7 LAMEA CHEMILUMINESCENCE IMMUNOASSAY (CLISA) MARKET, 2016-2023 ($MILLION)
FIGURE 8 LAMEA FLUORESCENCE IMMUNOASSAY (FIA) MARKET, 2016-2023 ($MILLION)
FIGURE 9 LAMEA COLORIMETRIC IMMUNOASSAY (CI) MARKET, 2016-2023 ($MILLION)
FIGURE 10 LAMEA RAPID TESTS MARKET, 2016-2023 ($MILLION)
FIGURE 11 LAMEA ENZYME-LINKED IMMUNOSPOT (ELISPOT) MARKET, 2016-2023 ($MILLION)
FIGURE 12 LAMEA RADIOIMMUNOASSAY (RIA) MARKET, 2016-2023 ($MILLION)
FIGURE 13 LAMEA WESTERN BLOT TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 14 LAMEA POLYMERIZE CHAIN REACTION PCR MARKET, 2016-2023 ($MILLION)
FIGURE 15 LAMEA ISOTHERMAL NUCLEIC ACID TECHNOLOGY (INAAT) MARKET, 2016-2023 ($MILLION)
FIGURE 16 LAMEA HYBRIDIZATION MARKET, 2016-2023 ($MILLION)
FIGURE 17 LAMEA DNA DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18 LAMEA MICROARRAY MARKET, 2016-2023 ($MILLION)
FIGURE 19 LAMEA OTHER MOLECULAR DIAGNOSTIC TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 20 LAMEA BASIC METABOLIC PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 21 LAMEA LIVER PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 22 LAMEA RENAL PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 23 LAMEA LIPID PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 24 LAMEA THYROID FUNCTION PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 25 LAMEA ELECTROLYTE PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 26 LAMEA SPECIALITY CHEMICALS MARKET, 2016-2023 ($MILLION)
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 30 ALERE INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 31 ALERE INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 32 ALERE INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 33 BIOMERIEUX REVENUE: 2014-2016 ($MILLION)
FIGURE 34 BIOMERIEUX: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 35 BIOMERIEUX: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 36 DANAHER CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 37 DANAHER CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 38 DANAHER CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 39 ROCHE DIAGNOSTICS: REVENUE, 2014-2016 ($MILLION)
FIGURE 40 ROCHE DIAGNOSTICS: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 41 BECTON, DICKINSON AND COMPANY: REVENUE, 2014-2016 ($MILLION)
FIGURE 42 BECTON DICKINSON AND COMPANY: REVENUES BY SEGMENT (%) (2016)
FIGURE 43 BECTON DICKINSON AND COMPANY: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 44 BIO-RAD LABORATORIES: REVENUE, 2014-2016 ($MILLION)
FIGURE 45 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 46 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 47 BAYER AG: REVENUE, 2014-2016 ($MILLION)
FIGURE 48 BAYER AG: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 49 SYSMEX CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 50 SYSMEX CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 51 SYSMEX CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 52 JOHNSON & JOHSNON: REVENUE, 2014 - 2016 ($MILLION)
FIGURE 53 JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 54 JOHNSON & JOHNSON: REVENUE SHARE BY GEOGRAPHY, (%)(2016)
FIGURE 1 MARKET SEGMENTATION
FIGURE 2 TOP INVESTMENT POCKETS
FIGURE 3 TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4 TOP WINNING STRATEGIES: NATURE AND TYPE, 2014-2016
FIGURE 5 PORTERS FIVE FORCES ANALYSIS
FIGURE 6 MARKET SHARE ANALYSIS: IVD MARKET, 2016
FIGURE 7 LAMEA CHEMILUMINESCENCE IMMUNOASSAY (CLISA) MARKET, 2016-2023 ($MILLION)
FIGURE 8 LAMEA FLUORESCENCE IMMUNOASSAY (FIA) MARKET, 2016-2023 ($MILLION)
FIGURE 9 LAMEA COLORIMETRIC IMMUNOASSAY (CI) MARKET, 2016-2023 ($MILLION)
FIGURE 10 LAMEA RAPID TESTS MARKET, 2016-2023 ($MILLION)
FIGURE 11 LAMEA ENZYME-LINKED IMMUNOSPOT (ELISPOT) MARKET, 2016-2023 ($MILLION)
FIGURE 12 LAMEA RADIOIMMUNOASSAY (RIA) MARKET, 2016-2023 ($MILLION)
FIGURE 13 LAMEA WESTERN BLOT TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 14 LAMEA POLYMERIZE CHAIN REACTION PCR MARKET, 2016-2023 ($MILLION)
FIGURE 15 LAMEA ISOTHERMAL NUCLEIC ACID TECHNOLOGY (INAAT) MARKET, 2016-2023 ($MILLION)
FIGURE 16 LAMEA HYBRIDIZATION MARKET, 2016-2023 ($MILLION)
FIGURE 17 LAMEA DNA DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18 LAMEA MICROARRAY MARKET, 2016-2023 ($MILLION)
FIGURE 19 LAMEA OTHER MOLECULAR DIAGNOSTIC TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 20 LAMEA BASIC METABOLIC PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 21 LAMEA LIVER PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 22 LAMEA RENAL PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 23 LAMEA LIPID PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 24 LAMEA THYROID FUNCTION PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 25 LAMEA ELECTROLYTE PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 26 LAMEA SPECIALITY CHEMICALS MARKET, 2016-2023 ($MILLION)
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 30 ALERE INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 31 ALERE INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 32 ALERE INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 33 BIOMERIEUX REVENUE: 2014-2016 ($MILLION)
FIGURE 34 BIOMERIEUX: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 35 BIOMERIEUX: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 36 DANAHER CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 37 DANAHER CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 38 DANAHER CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 39 ROCHE DIAGNOSTICS: REVENUE, 2014-2016 ($MILLION)
FIGURE 40 ROCHE DIAGNOSTICS: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 41 BECTON, DICKINSON AND COMPANY: REVENUE, 2014-2016 ($MILLION)
FIGURE 42 BECTON DICKINSON AND COMPANY: REVENUES BY SEGMENT (%) (2016)
FIGURE 43 BECTON DICKINSON AND COMPANY: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 44 BIO-RAD LABORATORIES: REVENUE, 2014-2016 ($MILLION)
FIGURE 45 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 46 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 47 BAYER AG: REVENUE, 2014-2016 ($MILLION)
FIGURE 48 BAYER AG: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 49 SYSMEX CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 50 SYSMEX CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 51 SYSMEX CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 52 JOHNSON & JOHSNON: REVENUE, 2014 - 2016 ($MILLION)
FIGURE 53 JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 54 JOHNSON & JOHNSON: REVENUE SHARE BY GEOGRAPHY, (%)(2016)
